YSCH-01

BIOLOGICAL2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Huashan Hospital

Conditions

Advanced Solid TumorsMetastatic Solid TumorsRare Malignant NeoplasmRecurrent Glioblastoma

Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

RecruitingNCT07538128

Huashan HospitalRecurrent Glioblastoma

Start: 2025-01-09End: 2027-02-28Target: 10Updated: 2026-04-20

Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruitingNCT07307053

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Solid Tumors, Metastatic Solid Tumors, Rare Malignant Neoplasm

Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29